XENON PHARMACEUTICALS INC. (XENE) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2017-12-31..
Gross margin
Overview →Financial period ending 2017-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2017-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 311.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2017-12-31 | (m) | $311.00K | (m) | (m) |
| 2017-09-30 | (m) | $671.00K | (m) | (m) |
| 2017-06-30 | (m) | $820.00K | (m) | (m) |
| 2017-03-31 | (m) | $1.22M | (m) | (m) |
| 2016-12-31 | (m) | $1.80M | (m) | (m) |
| 2016-09-30 | (m) | $4.65M | (m) | (m) |
| 2016-06-30 | (m) | $8.54M | (m) | (m) |
| 2016-03-31 | (m) | $12.17M | (m) | (m) |
| 2015-12-31 | (m) | $15.58M | (m) | (m) |
| 2015-09-30 | (m) | $17.23M | (m) | (m) |
| 2015-06-30 | (m) | $26.13M | (m) | (m) |
| 2015-03-31 | (m) | $27.38M | (m) | (m) |
| 2014-12-31 | (m) | $28.37M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $26.67M | (m) | (m) |
| 2014-03-31 | (m) | $26.97M | (m) | (m) |
| 2013-12-31 | (m) | $27.36M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $14.31M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |